- Home
- PETS vs VTVT Comparison
PETS vs VTVT Comparison
Compare PETS & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- VTVT
- Stock Information
- Founded
- PETS 1996
- VTVT 2015
- Country
- PETS United States
- VTVT United States
- Employees
- PETS N/A
- VTVT N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- VTVT Health Care
- Exchange
- PETS Nasdaq
- VTVT Nasdaq
- Market Cap
- PETS 62.8M
- VTVT 56.7M
- IPO Year
- PETS N/A
- VTVT 2015
- Fundamental
- Price
- PETS $3.66
- VTVT $15.89
- Analyst Decision
- PETS Sell
- VTVT Strong Buy
- Analyst Count
- PETS 2
- VTVT 2
- Target Price
- PETS $3.35
- VTVT $35.50
- AVG Volume (30 Days)
- PETS 111.3K
- VTVT 5.8K
- Earning Date
- PETS 06-10-2025
- VTVT 05-15-2025
- Dividend Yield
- PETS N/A
- VTVT N/A
- EPS Growth
- PETS N/A
- VTVT N/A
- EPS
- PETS 0.02
- VTVT N/A
- Revenue
- PETS $247,010,000.00
- VTVT $17,000.00
- Revenue This Year
- PETS N/A
- VTVT N/A
- Revenue Next Year
- PETS N/A
- VTVT N/A
- P/E Ratio
- PETS $216.83
- VTVT N/A
- Revenue Growth
- PETS N/A
- VTVT N/A
- 52 Week Low
- PETS $2.90
- VTVT $12.12
- 52 Week High
- PETS $6.85
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- PETS 48.08
- VTVT 34.47
- Support Level
- PETS $3.56
- VTVT $15.91
- Resistance Level
- PETS $3.82
- VTVT $18.09
- Average True Range (ATR)
- PETS 0.18
- VTVT 1.06
- MACD
- PETS -0.01
- VTVT -0.68
- Stochastic Oscillator
- PETS 15.83
- VTVT 0.00
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.